Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr1520 Inhibitors

Olr1520 inhibitors are a specialized class of chemical compounds designed to selectively target and inhibit the Olr1520 receptor, a member of the olfactory receptor family within the G-protein coupled receptor (GPCR) superfamily. These receptors are integral to the olfactory system, where they play a critical role in detecting odorant molecules and initiating the signal transduction pathways that ultimately lead to the perception of smells. The Olr1520 receptor, like other olfactory receptors, functions by binding to specific ligands, which then trigger a cascade of intracellular events that result in the transmission of sensory information to the brain. Olr1520 inhibitors are designed to disrupt this process by binding to the receptor in a way that blocks its natural ligands from activating it. This inhibition can be achieved either through direct competition at the receptor's active site, where the natural ligands would typically bind, or by interacting with allosteric sites, which can induce conformational changes that reduce the receptor's ability to function.

The development of Olr1520 inhibitors involves a thorough and systematic approach to optimizing various chemical properties, such as binding affinity, selectivity, and stability. Researchers utilize molecular modeling and docking simulations to predict how these inhibitors will interact with the Olr1520 receptor, providing insights into potential binding sites and the structural features necessary for effective inhibition. High-throughput screening of chemical libraries is often employed to identify lead compounds that show promising inhibitory effects against Olr1520. Once these leads are identified, structure-activity relationship (SAR) studies are conducted to refine the chemical structures of the inhibitors, enhancing their potency and selectivity while minimizing off-target effects. These studies might involve modifying the core chemical scaffold or altering functional groups to improve interactions with the receptor. Additionally, properties such as solubility, lipophilicity, and metabolic stability are carefully considered to ensure that the inhibitors can function effectively in various biological environments. By developing these inhibitors, researchers gain valuable insights into the molecular mechanisms of olfactory receptor function and contribute to a broader understanding of GPCR-mediated signal transduction in sensory perception.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Propranolol

525-66-6sc-507425
100 mg
$180.00
(0)

Beta-adrenergic antagonist, could modulate GPCR activity, potentially affecting Olr1520.

Carvedilol

72956-09-3sc-200157
sc-200157A
sc-200157B
sc-200157C
sc-200157D
100 mg
1 g
10 g
25 g
100 g
$124.00
$240.00
$530.00
$999.00
$1530.00
2
(1)

Beta-adrenergic antagonist with alpha-1 blocking, might influence Olr1520 signaling pathways.

Yohimbine hydrochloride

65-19-0sc-204412
sc-204412A
sc-204412B
1 g
5 g
25 g
$51.00
$171.00
$530.00
2
(1)

Alpha-2 adrenergic receptor antagonist, could affect GPCR signaling pathways related to Olr1520.

Labetalol

36894-69-6sc-484723
50 mg
$180.00
(0)

Combined alpha and beta blocker, might indirectly affect GPCR pathways including Olr1520.

Pindolol

13523-86-9sc-204847
sc-204847A
100 mg
1 g
$194.00
$760.00
(1)

Beta-adrenergic antagonist, may influence GPCR-mediated signaling pathways related to Olr1520.

Isoproterenol Hydrochloride

51-30-9sc-202188
sc-202188A
100 mg
500 mg
$28.00
$38.00
5
(0)

Beta-adrenergic agonist, might indirectly affect Olr1520 through GPCR modulation.

Atropine

51-55-8sc-252392
5 g
$204.00
2
(1)

Muscarinic acetylcholine receptor antagonist, may influence GPCR signaling pathways including Olr1520.

Salmeterol

89365-50-4sc-224277
sc-224277A
10 mg
50 mg
$186.00
$562.00
1
(1)

Beta-2 adrenergic agonist, potentially affecting GPCR pathways related to Olr1520.

Alprenolol

13655-52-2sc-507469
50 mg
$130.00
(0)

Beta blocker, could indirectly influence GPCR signaling pathways including Olr1520.